The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

adarepharma.com

Founded Year

1999

Stage

Acq - Fin - III | Alive

Revenue

$0000 

About Adare Pharmaceuticals

Adare Pharmaceuticals is a privately held, specialty pharmaceutical company providing effective therapies for unmet medical needs including cystic fibrosis and gastrointestinal disorders. Adare has manufacturing and commercial operations in the United States, the European Union and Canada, and its products include ZENPEP, CANASA, CARAFATE, PYLERA, RECTIV, VIOKACE, ULTRESA LACTEOL, DELURSAN, PANZYTRAT, and SALOFALK. Aptalis also formulates and clinically develops enhanced pharmaceutical and biopharmaceutical products for itself and others using its proprietary technology platforms including bioavailability enhancement of poorly soluble drugs, custom release profiles, and taste-masking/orally disintegrating tablet (ODT) formulations.

Adare Pharmaceuticals Headquarter Location

1200 Lenox Drive Suite 100

Lawrenceville, New Jersey, 08648,

United States

609-450-1312

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Adare Pharmaceuticals Patents

Adare Pharmaceuticals has filed 53 patents.

The 3 most popular patent topics include:

  • Dosage forms
  • Drug delivery devices
  • Pharmacokinetics
patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/23/2019

11/9/2021

Glucocorticoids, Pregnanes, Fluoroarenes, Diketones, Corticosteroid esters

Grant

Application Date

9/23/2019

Grant Date

11/9/2021

Title

Related Topics

Glucocorticoids, Pregnanes, Fluoroarenes, Diketones, Corticosteroid esters

Status

Grant

Latest Adare Pharmaceuticals News

Acquiring Activ Nutritional Is Perfect for Growth, Says Guardion Health Sciences

Jun 25, 2021

Share: Guardion Health Sciences Inc. (NASDAQ: GHSI ) is confident that its recent acquisition of  Activ Nutritional LLC  will be a strong catalyst for growth. The company successfully entered into an equity purchase agreement with Adare Pharmaceuticals Inc. in June this year to acquire all the equity of Activ Nutritional for $26 million. Adare owned the  Viactiv®  line of supplement chews for bone health, immune health, and other applications. The products are primarily marketed through many of the United States' largest retailers, including Walmart (retail and online), Target, and Amazon. In addition, the company is developing it directly to the consumer sales channel. The Viactiv product lines are expected to become Guardion's most prominent and provide access to significant opportunities in the short term for growth and expansion. Commenting on the significance of the acquisition, Bret Scholtes, Guardion's CEO, said the deal "satisfies a number of our current objectives as we continue efforts to build our position within the clinical nutrition market. Activ Nutritional has an established brand and presence from which we can significantly expand our capabilities in marketing, product lines, and new distribution channels. It also will provide a significant boost to our current revenue and operating earnings." "The transaction immediately expands our reach beyond ocular health, which has long been our primary focus, and allows us to explore opportunities in the wider world of clinical nutrition more easily," he added. Scholtes further explained exclusively to  Benzinga.com  that the deal is exciting. "It's going to take a little bit of time, but we think that we have distribution channels that will get us there. As a result of this acquisition, we think we have a strong brand in Viactiv, which we can help to drive some other businesses." Scholtes noted that the Viactiv brand has been around for about 20 years. Guardion Health Sciences is enthusiastic about the prospects for the future with the company now in its fold. "Our company is small and in the early stages of growth, but we are optimistic about our ability to create a clinical nutrition business — a nutrition business that's backed by clinical science," Scholtes added. About Guardion Health Sciences Guardion Health Sciences  is a clinical nutrition and diagnostics company that offers a portfolio of science-based, clinically supported nutrition, medical foods, supplements, and diagnostic products that support healthcare professionals, their patients, and consumers in achieving health goals. Guardion's commercial and developmental initiatives are supported by equally impressive scientific and medical advisory boards, led by seasoned business executives and physicians with many years of experience. Medical Foods The medical foods developed, manufactured, and distributed by Guardion Health Sciences, Lumega-Z, and GlaucoCetin, are designed specifically for the dietary management of specific conditions. Lumega-Z is designed to restore and replenish a depleted macular pigment, and GlaucoCetin is designed to reverse underlying mitochondrial dysfunction in optic nerve cells. A depleted macular pigment is a significant risk factor for macular degeneration, while mitochondrial dysfunction leads to optic nerve damage and vision loss in glaucoma patients. © 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • When was Adare Pharmaceuticals founded?

    Adare Pharmaceuticals was founded in 1999.

  • Where is Adare Pharmaceuticals's headquarters?

    Adare Pharmaceuticals's headquarters is located at 1200 Lenox Drive, Lawrenceville.

  • What is Adare Pharmaceuticals's latest funding round?

    Adare Pharmaceuticals's latest funding round is Acq - Fin - III.

  • Who are the investors of Adare Pharmaceuticals?

    Investors of Adare Pharmaceuticals include Frazier Healthcare Partners, Thomas H. Lee Partners, TPG Capital, Allergan and Forest Laboratories.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.